RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer.
Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
该研究揭示了 CD56 Bright NK、CD56 Dim NK、NKT 样细胞和 T 细胞上的差异性受体表达谱、细胞因子水平和可溶性配体,这些可能被用于为 HGSOC 患者开发替代治疗方法。
卵巢癌是印度女性第三常见的癌症。印度高级别浆液性上皮性卵巢癌(HGSOC)的相对发生比例及相关死亡率均较高,因此有必要了解其免疫特征以改进治疗方式。本研究分析原发和复发HGSOC患者的NK细胞受体表达、相应配体、血清细胞因子及可溶性配体。研究使用多色流式细胞术对肿瘤浸润及循环淋巴细胞进行免疫表型分析,并采用Procartaplex和ELISA测定可溶性配体和细胞因子。纳入的51名上皮性卵巢癌患者中,33名为原发性HGSOC,18名为复发患者;另以46名年龄匹配健康对照作比较。结果显示,两组患者循环CD56明亮型NK、CD56暗型NK、NKT样细胞和T细胞中表达活化受体的亚群比例降低,同时表达抑制性受体的免疫亚群也发生改变。原发和复发卵巢癌患者的免疫特征存在差异。两组患者可溶性MICA均升高,可能作为“诱饵”分子,导致NKG2D阳性亚群减少。卵巢癌患者血清IL-2、IL-5、IL-6、IL-10和TNF水平升高,可能与疾病进展有关。肿瘤浸润免疫细胞分析发现,两组患者DNAM-1阳性NK细胞和T细胞水平均低于其循环对应细胞,这可能削弱NK细胞形成免疫突触的能力。结论:不同CD56明亮型NK、CD56暗型NK、NKT样细胞和T细胞的受体表达、细胞因子水平及可溶性配体特征,可能为HGSOC替代治疗策略的开发提供依据。原发和复发病例的循环免疫特征存在一些差异,提示原发肿瘤的免疫特征在循环中发生变化,可能促进复发;同时两组也保留一些共同特征,包括NKG2D表达降低、MICA升高以及IL-6、IL-10和TNF升高,提示卵巢癌患者存在难以逆转的免疫抑制。研究还指出,恢复细胞因子水平以及肿瘤浸润免疫细胞上的NKG2D和DNAM-1,可能成为开发HGSOC特异性治疗策略的方向。
Ovarian cancer is the third most prevalent cancer in Indian women. Relative frequency of High grade serous epithelial ovarian cancer (HGSOC) and its associated deaths are highest in India which suggests the importance of understanding their immune profiles for better treatment modality. Hence, the present study investigated the NK cell receptor expression, their cognate ligands, serum cytokines, and soluble ligands in primary and recurrent HGSOC patients. We have used multicolor flow cytometry for immunophenotyping of tumor infiltrated and circulatory lymphocytes. Procartaplex, and ELISA were used to measure soluble ligands and cytokines of HGSOC patients.
Among the enrolled 51 EOC patients, 33 were primary high grade serous epithelial ovarian cancer (pEOC) and 18 were recurrent epithelial ovarian cancer (rEOC) patients. Blood samples from 46 age matched healthy controls (HC) were used for comparative analysis. Results revealed, frequency of circulatory CD56 Bright NK, CD56 Dim NK, NKT-like, and T cells was reduced with activating receptors while alterations in immune subsets with inhibitory receptors were observed in both groups. Study also highlights differential immune profile of primary and recurrent ovarian cancer patients. We have found increased soluble MICA which might have acted as "decoy" molecule and could be a reason of decrease in NKG2D positive subsets in both groups of patients. Furthermore, elevated level of serum cytokines IL-2, IL-5, IL-6, IL-10, and TNF- in ovarian cancer patients, might be associated with ovarian cancer progression. Profiling of tumor infiltrated immune cells revealed the reduced level of DNAM-1 positive NK and T cells in both groups than their circulatory counterpart, which might have led to decrease in NK cell's ability of synapse formation.
The study brings out differential receptor expression profile on CD56 Bright NK, CD56 Dim NK, NKT-like, and T cells, cytokines levels and soluble ligands which may be exploited to develop alternate therapeutic approaches for HGSOC patients. Further, few differences in the circulatory immune profiles between pEOC and rEOC cases, indicates the immune signature of pEOC undergoes some changes in circulation that might facilitated the disease relapse. They also maintains some common immune signatures such as reduced expression of NKG2D, high level of MICA as well as IL-6, IL10 and TNF- , which indicates irreversible immune suppression of ovarian cancer patients. It is also emphasized that a restoration of cytokines level, NKG2D and DNAM-1on tumor infiltrated immune cells may be targeted to develop specific therapeutic approaches for high-grade serous epithelial ovarian cancer.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。